Fmr LLC Trims Stock Position in Pfizer Inc. (NYSE:PFE)

FMR LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 25.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,756,020 shares of the biopharmaceutical company's stock after selling 3,722,469 shares during the quarter. FMR LLC owned about 0.19% of Pfizer worth $285,357,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in PFE. Retirement Wealth Solutions LLC acquired a new stake in Pfizer during the 4th quarter worth about $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer during the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC acquired a new position in Pfizer in the fourth quarter valued at approximately $31,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 0.9 %

PFE traded up $0.19 on Monday, hitting $22.10. The company had a trading volume of 61,888,490 shares, compared to its average volume of 40,318,751. The company's fifty day moving average price is $25.25 and its 200 day moving average price is $26.38. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $125.34 billion, a P/E ratio of 15.67, a PEG ratio of 0.64 and a beta of 0.67.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the previous year, the firm earned $0.10 EPS. The business's revenue was up 24.7% on a year-over-year basis. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on PFE shares. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group reduced their target price on Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a research note on Tuesday, April 8th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $31.07.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.